H.I.G. BioVentures has stepped up to lead a $34 million round for Seattle-based Cardeas Pharma, which is developing new antibiotics for drug-resistant bacterial infections.
In a bid to join the billion-dollar sales club, the UK's BTG has snapped up a pair of operations with new delivery tech and a treatment for deep vein thrombosis for up to $420 million—most of that in cash. And it's selling a chunk of shares to help pay for it all.
A group of ex-oil traders who created a new private equity group dubbed Hydra has decided to back the two lead programs at Seattle-based Kineta. There's no word on just how much they're investing in the biotech, but the "major investment" will be used to develop ShK-186, a Phase I immune-sparing autoimmune disease drug, and rOAS, a pan-viral therapeutic "aimed at an array of high priority contagious pathogens" now headed into the clinic.
Natick, MA-based Karyopharm Therapeutics has banked $48.2 million in Series B cash. The funds will be used to advance its pipeline of selective inhibitors of nuclear export (SINE) drug candidates for hematologic and solid tumors.
Effector Therapeutics has rallied marquee investors for a sizable $45 million Series A financing, determined to use discoveries in protein translation to mine for new cancer drugs.
Merck KGaA signaled Thursday that it will make a bigger commitment to investing in emerging biotech companies.
For Amgen and Novartis, investing in the latest fund from Atlas Venture wasn't enough. The Cambridge, MA-based venture firm has struck separate agreements with the two major drugmakers to join forces on biotech startups.
Los Angeles-based biotech startup Kite Pharma has locked in $20 million in a private placement with its new investor Alta Partners and previous backers. By converting $15 million in previous promissory notes to stock, the company has increased the first-round financing to $35 million.
Just a few weeks after bidding farewell to its longtime CEO, Cambridge, MA-based Tokai Pharmaceuticals has rounded up $35.5 million in Series E cash to push into an expanded mid-stage study of its triple-threat treatment for prostate cancer.
Alnylam Pharmaceuticals CEO John Maraganore has joined Third Rock in the advisory role of venture partner, reunited in a way with his former Millennium Pharmaceuticals colleagues who launched the venture firm 6 years ago.